Batavia Biosciences is a contract development and manufacturing organization with expertise in viral vaccines, virotherapy, proteins and antibodies. We are not your standard CDMO – our customers regularly refer to us as their product development partner and thought partner.
How Batavia helps to reduce human suffering from infectious diseases and cancer
We accelerate the journey to the clinic by improving product yields, reducing process development time and increasing product stability. Our services and technologies have demonstrated to reduce risks, improve timelines and reduce costs in biopharmaceutical development to ensure the product reaches the patient without any unnecessary delays.
100
experts with industry experience
500
projects successfully completed
97
successful runs under GMP
70
returning customers
Latest resources from learning center
Leiden, The Netherlands, June 14, 2022 – Today, Batavia Biosciences announces the expansion of its headquarters and R&D capacities in the Netherlands. The infrastructure increases capacity with another 22,500 sq.…
Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective
Adenoviruses are being explored as vectors for cardiovascular gene therapy purposes against many heritable diseases. Gene transfer vectors, based on human adenovirus serotype 5, were some of the first developed…
Date: 16-19 May Location: Washington, USA Contact: Bjorn te Boekhorst Meet us at the 25th American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting in Washington D.C. from May…
Date: 17- 20 May 2022 Location: Vienna, Austria Contact: Pieter-Jan Vos Will you be joining us at BPI Europe? Our team looks forward to meeting you in person again at…
Talk to our experts
